UNITED THERAP
SpecialtyUNITED THERAP is a specialty pharmaceutical company focused on Respiratory, Cardiovascular, Oncology. Key products include UNITUXIN.
UNITED THERAP at a Glance
- Fast trial execution (30 months median completion)
UNITED THERAP's Key Drugs
UNITED THERAP's core commercial portfolio centers on TYVASO DPI, ORENITRAM, UNITUXIN, spanning Respiratory and Cardiovascular — its most strategically important drugs approved in the last 15 years.
UNITED THERAP's Recent FDA Approvals
New NDA/BLA approvals for UNITED THERAP over the last two years — novel drugs only, excluding generics and label supplements.
UNITED THERAP's Therapeutic Areas
UNITED THERAP's approved drugs and pipeline span 3 therapeutic areas, led by Respiratory and Cardiovascular, across 1 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
UNITED THERAP's Top Competitors
UNITED THERAP's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Bayer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
UNITED THERAP Pipeline Snapshot
UNITED THERAP has 90 active clinical programs from ClinicalTrials.gov — 36 Phase 3, 23 Phase 2 and 31 Phase 1.
Phase 3 Readout Calendar Pro
5 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 7/20 completed
- • Speed: 30 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (3)
Discontinued (0)
Company Info
- First Approval
- 2002-05-21
- Latest
- 2026-04-03
- Applications
- 6
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges